PMC

Glioblastoma Multiforme (GBM), the most common primary brain tumor in adults, has a median survival rate of 12 months, even with aggressive resection and radiation therapy (). Regrettably, outcomes for this disease have not substantially improved since the Brain Tumor Study Group published their results over 25 years ago. The current standard of care for GBM consists of surgery followed by adjuvant radiotherapy. Although numerous phase III trials have attempted to demonstrate the benefit of employing chemotherapy in these patients, either concomitantly with radiotherapy or as isolated adjuvant treatment, a significant prolongation of survival has never been documented.